Lung Cancer

16 protocols meet the specified criteria.

• 20240178

  A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

• A081801

  Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO

• A151804

  Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

• A211901

  Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

• EA5231

  A Randomized Phase III Trial of Checkpoint blockade in Lung cancer patients in the Adjuvant setting based on pathologic Response following neoadjuvant therapy

• EAY191

  Molecular Analysis for Combination Therapy Choice (ComboMATCH)

• EAY191-N5

  A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

• GRAIL-MA-002

  REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

• LUNGMAP

  A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

• NRG-CC014

  Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

• NRG-LU007

  Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

• NRG-LU008

  Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

• PRESERVE-003

  Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

• S1800E

  LUNGMAP: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Non-Matched Sub-Study)

• S1900J

  A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNGMAP Sub-Study)

• S1900K

  A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-small Cell Lung Cancer (Lung-Map Sub-Study)